# Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct05651022/  
OnCo record `nct05651022` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Tislelizumab in hepatocellular carcinoma and colorectal cancer, run by Indaptus Therapeutics, Inc, active and no longer recruiting.

## Summary

Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05651022 by Indaptus Therapeutics, Inc, with 120 participants planned, started 2023-02-28 and due to reach its primary completion in 2027-06-30. Interventions recorded: Decoy20, Tislelizumab. Conditions listed: Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Pancreatic Adenocarcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05651022
- Phase: 1/2
- Setting: A Phase 1/2, Open-Label, Multi-Center, Dose Escalation and Expansion Study Evaluating the Safety, Tolerability and Clinical Activity of DECOY20 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced Solid Tumors
- Sponsor: Indaptus Therapeutics, Inc
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT05651022: https://clinicaltrials.gov/study/NCT05651022

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Tislelizumab](https://onco.cc/drugs/tislelizumab/)

---
JSON: https://onco.cc/api/v1/entities/nct05651022.json